Not applicableEnded earlyNCT02716077What this trial is testingEarly FDG PET in MelanomaWho this might be right forClinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma Abramson Cancer Center at Penn Medicine 6